294 related articles for article (PubMed ID: 10439042)
1. PAX3 and PAX7 exhibit conserved cis-acting transcription repression domains and utilize a common gain of function mechanism in alveolar rhabdomyosarcoma.
Bennicelli JL; Advani S; Schäfer BW; Barr FG
Oncogene; 1999 Jul; 18(30):4348-56. PubMed ID: 10439042
[TBL] [Abstract][Full Text] [Related]
2. Mechanism for transcriptional gain of function resulting from chromosomal translocation in alveolar rhabdomyosarcoma.
Bennicelli JL; Edwards RH; Barr FG
Proc Natl Acad Sci U S A; 1996 May; 93(11):5455-9. PubMed ID: 8643596
[TBL] [Abstract][Full Text] [Related]
3. Gene fusions involving PAX and FOX family members in alveolar rhabdomyosarcoma.
Barr FG
Oncogene; 2001 Sep; 20(40):5736-46. PubMed ID: 11607823
[TBL] [Abstract][Full Text] [Related]
4. Wild type PAX3 protein and the PAX3-FKHR fusion protein of alveolar rhabdomyosarcoma contain potent, structurally distinct transcriptional activation domains.
Bennicelli JL; Fredericks WJ; Wilson RB; Rauscher FJ; Barr FG
Oncogene; 1995 Jul; 11(1):119-30. PubMed ID: 7624119
[TBL] [Abstract][Full Text] [Related]
5. Detection of PAX3-FKHR and PAX7-FKHR fusion transcripts in rhabdomyosarcoma by reverse transcriptase-polymerase chain reaction using paraffin-embedded tissue.
Chen BF; Chen ML; Liang DC; Huang YW; Liu HC; Chen SH
Zhonghua Yi Xue Za Zhi (Taipei); 1999 Feb; 62(2):86-91. PubMed ID: 10063718
[TBL] [Abstract][Full Text] [Related]
6. Co-expression of alternatively spliced forms of PAX3, PAX7, PAX3-FKHR and PAX7-FKHR with distinct DNA binding and transactivation properties in rhabdomyosarcoma.
Du S; Lawrence EJ; Strzelecki D; Rajput P; Xia SJ; Gottesman DM; Barr FG
Int J Cancer; 2005 May; 115(1):85-92. PubMed ID: 15688409
[TBL] [Abstract][Full Text] [Related]
7. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.
Sorensen PH; Lynch JC; Qualman SJ; Tirabosco R; Lim JF; Maurer HM; Bridge JA; Crist WM; Triche TJ; Barr FG
J Clin Oncol; 2002 Jun; 20(11):2672-9. PubMed ID: 12039929
[TBL] [Abstract][Full Text] [Related]
8. Common and variant gene fusions predict distinct clinical phenotypes in rhabdomyosarcoma.
Kelly KM; Womer RB; Sorensen PH; Xiong QB; Barr FG
J Clin Oncol; 1997 May; 15(5):1831-6. PubMed ID: 9164192
[TBL] [Abstract][Full Text] [Related]
9. The role of chimeric paired box transcription factors in the pathogenesis of pediatric rhabdomysarcoma.
Barr FG
Cancer Res; 1999 Apr; 59(7 Suppl):1711s-1715s. PubMed ID: 10197585
[TBL] [Abstract][Full Text] [Related]
10. Fusion genes resulting from alternative chromosomal translocations are overexpressed by gene-specific mechanisms in alveolar rhabdomyosarcoma.
Davis RJ; Barr FG
Proc Natl Acad Sci U S A; 1997 Jul; 94(15):8047-51. PubMed ID: 9223312
[TBL] [Abstract][Full Text] [Related]
11. Fusion of PAX7 to FKHR by the variant t(1;13)(p36;q14) translocation in alveolar rhabdomyosarcoma.
Davis RJ; D'Cruz CM; Lovell MA; Biegel JA; Barr FG
Cancer Res; 1994 Jun; 54(11):2869-72. PubMed ID: 8187070
[TBL] [Abstract][Full Text] [Related]
12. Genetic heterogeneity in the alveolar rhabdomyosarcoma subset without typical gene fusions.
Barr FG; Qualman SJ; Macris MH; Melnyk N; Lawlor ER; Strzelecki DM; Triche TJ; Bridge JA; Sorensen PH
Cancer Res; 2002 Aug; 62(16):4704-10. PubMed ID: 12183429
[TBL] [Abstract][Full Text] [Related]
13. Detection of the PAX3-FKHR fusion gene in paediatric rhabdomyosarcoma: a reproducible predictor of outcome?
Anderson J; Gordon T; McManus A; Mapp T; Gould S; Kelsey A; McDowell H; Pinkerton R; Shipley J; Pritchard-Jones K;
Br J Cancer; 2001 Sep; 85(6):831-5. PubMed ID: 11556833
[TBL] [Abstract][Full Text] [Related]
14. In vivo amplification of the PAX3-FKHR and PAX7-FKHR fusion genes in alveolar rhabdomyosarcoma.
Barr FG; Nauta LE; Davis RJ; Schäfer BW; Nycum LM; Biegel JA
Hum Mol Genet; 1996 Jan; 5(1):15-21. PubMed ID: 8789435
[TBL] [Abstract][Full Text] [Related]
15. PAX3/forkhead homolog in rhabdomyosarcoma oncoprotein activates glucose transporter 4 gene expression in vivo and in vitro.
Armoni M; Quon MJ; Maor G; Avigad S; Shapiro DN; Harel C; Esposito D; Goshen Y; Yaniv I; Karnieli E
J Clin Endocrinol Metab; 2002 Nov; 87(11):5312-24. PubMed ID: 12414908
[TBL] [Abstract][Full Text] [Related]
16. The alveolar rhabdomyosarcoma PAX3/FKHR fusion protein is a transcriptional activator.
Sublett JE; Jeon IS; Shapiro DN
Oncogene; 1995 Aug; 11(3):545-52. PubMed ID: 7630639
[TBL] [Abstract][Full Text] [Related]
17. Proliferative and apoptotic differences between alveolar rhabdomyosarcoma subtypes: a comparative study of tumors containing PAX3-FKHR or PAX7-FKHR gene fusions.
Collins MH; Zhao H; Womer RB; Barr FG
Med Pediatr Oncol; 2001 Aug; 37(2):83-9. PubMed ID: 11496344
[TBL] [Abstract][Full Text] [Related]
18. Novel formation and amplification of the PAX7-FKHR fusion gene in a case of alveolar rhabdomyosarcoma.
Weber-Hall S; McManus A; Anderson J; Nojima T; Abe S; Pritchard-Jones K; Shipley J
Genes Chromosomes Cancer; 1996 Sep; 17(1):7-13. PubMed ID: 8889501
[TBL] [Abstract][Full Text] [Related]
19. The PAX3-FKHR fusion protein created by the t(2;13) translocation in alveolar rhabdomyosarcomas is a more potent transcriptional activator than PAX3.
Fredericks WJ; Galili N; Mukhopadhyay S; Rovera G; Bennicelli J; Barr FG; Rauscher FJ
Mol Cell Biol; 1995 Mar; 15(3):1522-35. PubMed ID: 7862145
[TBL] [Abstract][Full Text] [Related]
20. Structural analysis of PAX7 rearrangements in alveolar rhabdomyosarcoma.
Fitzgerald JC; Scherr AM; Barr FG
Cancer Genet Cytogenet; 2000 Feb; 117(1):37-40. PubMed ID: 10700864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
